Ray Therapeutics: Funding, Investors & Team (Sep 2026)
Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.
Ray Therapeutics has raised $225M across 2 funding rounds on record, the most recent a Series B of $125M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ray Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Ray Therapeutics Funding Rounds
Ray Therapeutics raised $100M in a Series A announced in May 2023.
2.9 years later, a Series B of $125M was announced in Apr 2026.
Ray Therapeutics Founders and Leadership Team
Contact details for the Ray Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Ray Therapeutics Funding Compared to Other Biotechnology Startups
Ray Therapeutics' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ray Therapeutics in Biotechnology and San Diego
Companies Similar to Ray Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Ray Therapeutics Funding FAQs
What does Ray Therapeutics do?
Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.
How much funding has Ray Therapeutics raised?
Ray Therapeutics has raised $225M across 2 rounds on record. The most recent is a Series B of $125M announced in Apr 2026.
When did Ray Therapeutics last raise funding?
Ray Therapeutics' most recent funding round on record is a Series B of $125M, announced in Apr 2026.
Who founded Ray Therapeutics?
FundedIQ lists Peter Francis (Founder), Terry O'neal (Founder) at Ray Therapeutics.
Where is Ray Therapeutics headquartered?
Ray Therapeutics is based in San Diego, California, United States.
How many employees does Ray Therapeutics have?
Ray Therapeutics is in the 11-50 employee band.
How does Ray Therapeutics' funding compare to other Biotechnology startups?
Ray Therapeutics' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Ray Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ray Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.